NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
MPS Limited Acquires Unbound Medicine to Target $188B Healthcare AI Market
MPS Limited has detailed its acquisition of Unbound Medicine, Inc., a US-based leader in healthcare knowledge management, to pivot toward high-growth AI-driven intelligence. Unbound brings a robust subscription-based model with over 90,000 paid subscribers and 1,000+ healthcare facility clients. The acquisition targets a healthcare AI market projected to reach $188 billion by 2030, with a specific subsector CAGR of 42%. MPS plans to leverage its global infrastructure to expand Unbound's reach beyond North America into Europe and APAC, aiming for significant EBITDA uplift.
முக்கிய அம்சங்கள்
Unbound Medicine serves 1,000+ healthcare facilities and manages 5 million+ clinical lookups annually.The business model is recurring revenue-based with low concentration risk; the largest customer contributes <$300,000.Targets the AI-driven knowledge management market, expected to grow from $3 billion to $102 billion by 2034.Acquisition includes a multidisciplinary team with an average tenure of 12 years and 20+ years of clinical expertise.Strategic alignment with 'Vision 2027' to transition MPS from a content provider to a global intelligence powerhouse.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this acquisition as it shifts the company toward high-margin, recurring SaaS revenue in the resilient healthcare sector. Monitor the speed of global rollout and EBITDA margin improvements in subsequent quarters as integration synergies kick in.
MPS Limited Schedules Investor Call on Feb 18 for Unbound Medicine, Inc. Acquisition
MPS Limited has announced an update to its conference call scheduled for February 18, 2026, at 7:00 P.M. IST regarding the acquisition of Unbound Medicine, Inc. The company has added a Zoom audio-video participation option to the existing dial-in facilities to facilitate better investor engagement. The acquisition is being conducted through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the call to discuss the strategic implications of this US-based expansion.
முக்கிய அம்சங்கள்
Conference call scheduled for February 18, 2026, at 7:00 P.M. IST.Discussion focused on the acquisition of Unbound Medicine, Inc., USA.Deal executed via MPS North America LLC, a 100% wholly-owned subsidiary.Management to provide details on the strategic rationale and financial impact of the US acquisition.
👀 கவனிக்க வேண்டியவை
Investors should attend the conference call to understand the valuation and synergy benefits of the Unbound Medicine acquisition. Monitor the impact of this acquisition on the company's North American revenue share and overall margins.
MPS Limited to Discuss Acquisition of Unbound Medicine Inc. in Upcoming Call
MPS Limited has scheduled a conference call for February 18, 2026, to provide details on the acquisition of Unbound Medicine, Inc., USA. The acquisition is being executed through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the discussion to explain the strategic rationale and expected synergies. This move highlights the company's ongoing focus on inorganic growth and expansion within the North American market.
முக்கிய அம்சங்கள்
Conference call scheduled for Wednesday, February 18, 2026, at 07:00 P.M. IST.Acquisition of US-based Unbound Medicine, Inc. by wholly-owned subsidiary MPS North America LLC.Chairman and CEO Rahul Arora and senior management to address institutional investors and analysts.Universal dial-in numbers for the event are +91 22 6280 1410 and +91 22 7115 8311.
👀 கவனிக்க வேண்டியவை
Investors should monitor the conference call for specific details regarding the acquisition cost, revenue multiples, and how this integration will impact the company's consolidated margins.
MPS Limited Completes Acquisition of Unbound Medicine, USA for USD 16.50 Million
MPS Limited, through its US subsidiary MPS North America LLC, has successfully completed the 100% acquisition of Unbound Medicine, Inc., USA. The transaction was finalized for a total consideration of USD 16.50 million following the satisfaction of customary closing conditions. As a result, Unbound Medicine has become a wholly-owned step-down subsidiary of MPS Limited effective February 9, 2026. This acquisition is part of the company's strategy to expand its footprint in the North American market and enhance its digital health and medical education offerings.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in Unbound Medicine, Inc., USA successfully completedTotal transaction value fixed at USD 16.50 million subject to customary adjustmentsUnbound Medicine is now a wholly-owned step-down subsidiary of MPS LimitedCompletion follows the Stock Purchase Agreement originally signed on January 30, 2026Funding arrangements for the acquisition were previously disclosed on February 4, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic growth move that strengthens MPS's international presence. Monitor upcoming quarterly results to assess the revenue contribution and margin impact of this new subsidiary.
MPS Ltd Q3 FY26: 9M Revenue INR 563.2 Cr, Unbound Medicine Acquisition for $16.5M
MPS Limited reported a steady 9M FY26 performance with revenue reaching INR 563.2 crores, despite a slight dip in Q3 revenue to INR 182.5 crores. The Education Solutions segment showed robust growth of 38% in the first nine months, while Research Solutions remained the anchor with 61.1% revenue contribution. A major highlight is the USD 16.5 million acquisition of Unbound Medicine, a high-margin subscription business in the medical and nursing sector. Management remains confident in surpassing an EPS of INR 100 for FY26, supported by aggressive cost optimization and new synergies.
முக்கிய அம்சங்கள்
9M FY26 revenue reached INR 563.2 crores with Education Solutions segment growing over 38%Q3 FY26 EBITDA margin stood at 31.6%, with the Education segment margins reaching 40.8%Research Solutions contributed 61.1% of 9M revenue with 16.2% organic growth excluding AJEAcquired 100% of Unbound Medicine for USD 16.5 million to secure high-margin recurring revenueManagement targets FY26 EPS to exceed INR 100, driven by cost optimization and platform synergies
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of Unbound Medicine as it shifts the business toward higher-margin recurring revenue. The management's confidence in achieving an EPS of INR 100+ suggests strong underlying profitability despite a transitional third quarter.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
MPS Ltd Finalizes Funding for $16.5M Acquisition of Unbound Medicine via Debt and Accruals
MPS Limited has outlined a comprehensive funding structure for its USD 16.50 million acquisition of Unbound Medicine, Inc. The acquisition will be financed through a mix of internal accruals, inter-company loans totaling USD 4.94 million, and a new INR 420 million term loan from ICICI Bank. The company is infusing USD 9.81 million as equity into its US subsidiary, MPS North America LLC, to facilitate the transaction. This structured financing ensures the acquisition proceeds without diluting the parent company's 100% stake in its US operations.
முக்கிய அம்சங்கள்
Total acquisition consideration for Unbound Medicine, Inc. is USD 16.50 million.Secured an INR 420 million term loan from ICICI Bank at a competitive interest rate of 7.85%.Inter-company loans of USD 3.00 million and USD 1.94 million arranged to optimize group liquidity.MPS Limited to infuse USD 9.81 million in equity into its wholly-owned subsidiary MPS North America LLC.Funding involves a balanced mix of internal cash reserves and external borrowings.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward inorganic growth, with a clear and structured financing plan in place. Monitor the integration of Unbound Medicine and its contribution to the company's consolidated revenue and margins in upcoming quarters.
MPS Ltd Q3 PAT at ₹24.7 Cr; 9M Profit Jumps 25.8% YoY; Director Resigns
MPS Limited reported a steady performance for the nine-month period ended December 2025, with standalone net profit rising 25.8% YoY to ₹81.68 crore. However, Q3 FY26 standalone revenue saw a marginal decline to ₹111.20 crore from ₹113.27 crore in the corresponding quarter last year. The company also announced the resignation of Ms. Yamini Tandon, a Non-Executive Director and Chairperson of the Stakeholders’ Relationship Committee, effective February 2, 2026. Additionally, the board approved the grant of 28,906 ESOPs to employees during the quarter.
முக்கிய அம்சங்கள்
Standalone Net Profit for 9M FY26 increased to ₹81.68 crore from ₹64.92 crore in 9M FY25.Q3 FY26 Revenue from operations stood at ₹111.20 crore, slightly down from ₹113.27 crore YoY.Basic Earnings Per Share (EPS) for the quarter ended December 31, 2025, was ₹14.44.Ms. Yamini Tandon resigned from the Board and all committees due to personal reasons.The company granted 28,906 stock options under the MPS Limited- Employee Stock Options Scheme 2023.
👀 கவனிக்க வேண்டியவை
Investors should look past the marginal Q3 revenue dip and focus on the strong 25.8% growth in nine-month profitability. Monitor the transition in the Stakeholders’ Relationship Committee following the director's resignation.
MPS Ltd Q3 FY26 Net Profit Rises 31.5% YoY to ₹28.52 Cr; Revenue Up 28% YoY
MPS Limited reported a strong year-on-year performance for Q3 FY26, with standalone revenue growing 28.2% to ₹111.20 crore compared to ₹86.74 crore in the previous year. Net profit for the quarter stood at ₹28.52 crore, marking a 31.5% increase YoY, despite a marginal 1.8% dip in revenue on a sequential basis. The company also announced the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to its Insider Trading Code. Additionally, the board noted the grant of 28,906 ESOPs to eligible employees during the quarter.
முக்கிய அம்சங்கள்
Standalone Revenue from operations grew 28.2% YoY to ₹11,120 lakhs in Q3 FY26.Net Profit increased by 31.5% YoY to ₹2,852 lakhs from ₹2,168 lakhs in the same quarter last year.Learning Solutions segment contributed ₹5,157 lakhs to revenue, while Content Solutions added ₹5,076 lakhs.Basic EPS improved significantly to ₹16.66 from ₹12.67 in the corresponding quarter of the previous year.Ms. Yamini Tandon resigned as Non-Executive Director effective February 2, 2026, due to personal reasons.
👀 கவனிக்க வேண்டியவை
Investors should take note of the robust year-on-year growth and healthy margins, which indicate strong operational execution. While the slight sequential revenue dip should be monitored, the overall financial trajectory remains positive for long-term holders.
MPS Limited Q3 FY26: PAT at ₹35.5 Cr; On Track for Record ₹100+ EPS in FY26
MPS Limited reported a resilient performance for Q3 FY26 with revenues of ₹182.5 crore, despite a marginal 2.1% YoY decline. The core Research Solutions segment (excluding AJE) showed strong growth of 16.2% YoY, while Education Solutions grew by 11.3%. The company remains debt-free with a strong cash position of ₹143 crore and is confident of achieving its first-ever annual EPS of ₹100+ for FY26. Profitability in Q3 was impacted by a ₹7.02 crore exceptional provision related to the New Labour Code.
முக்கிய அம்சங்கள்
9M FY26 PAT grew by 23.9% YoY to ₹126.2 crore, with EBITDA margins improving to 29.9%.Research Solutions (excl. AJE) revenue grew 16.2% YoY, maintaining a high EBITDA margin of 39.1%.Education Solutions segment revenue increased 11.3% YoY to ₹44.3 crore with 40.8% EBITDA margins.Company maintains a debt-free balance sheet with cash and equivalents of ₹143 crore as of Dec 2025.Management expects to surpass ₹100 EPS for the first time in the company's history in FY26.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong 9M growth trajectory and the management's confidence in achieving record EPS. The core strength in Research and Education segments makes this a solid long-term play despite the temporary reset in Corporate Learning.
MPS Limited Acquires 100% Stake in US-Based Healthcare Tech Firm Unbound Medicine
MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc., a Delaware-based healthcare technology company. Founded in 1999, Unbound Medicine provides digital medical reference and clinical decision-support solutions via a subscription-led institutional model. This acquisition marks MPS's strategic entry into the high-growth healthcare and medical information technology segment. The move aligns with the company's 'Vision 2027' strategy to focus on high-quality, recurring-revenue businesses with strong customer stickiness in the North American market.
முக்கிய அம்சங்கள்
Acquisition of 100% stake in Unbound Medicine, Inc. by wholly-owned subsidiary MPS North America LLC.Unbound Medicine has a 26-year operational history serving leading medical schools and hospital systems in the US and Canada.The target company operates a subscription-led business model, ensuring resilient and recurring revenue streams.Strategic expansion into the healthcare vertical, diversifying MPS's portfolio beyond core digital publishing.Integration with MPS Labs intended to accelerate AI-driven innovation in clinical tools and medical platforms.
👀 கவனிக்க வேண்டியவை
This acquisition is a significant positive as it adds a high-margin, recurring revenue stream in a specialized vertical. Investors should monitor upcoming financial disclosures for the deal valuation and the impact on consolidated EBITDA margins.
MPS Ltd to Acquire US-based Unbound Medicine for USD 16.5 Million
MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc. for USD 16.50 million in cash. Unbound Medicine is a healthcare learning technology company that reported USD 8.88 million in revenue for CY2024. The acquisition provides MPS entry into the high-growth medical information technology segment and adds over 480 institutional clients to its portfolio. This move is part of MPS's strategic vision to reach INR 1,500 crore in revenue by FY28.
முக்கிய அம்சங்கள்
Acquisition of 100% stake for a total cash consideration of USD 16.50 millionTarget entity reported CY2024 revenue of USD 8.88 million with a high gross retention rate of ~97%Adds 480+ institutional customers including medical schools and hospital systems across the US and CanadaStrategic entry into AI-enabled clinical decision support and healthcare learning platformsTransaction expected to be completed on or before 10 February 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive strategic expansion into a high-margin, recurring revenue vertical that complements MPS's existing digital publishing business. Monitor the integration progress and the impact on consolidated margins in upcoming quarters.
MPS Limited: Mrs. Geetika Hans Resigns as Chief People Officer
MPS Limited announced the resignation of Mrs. Geetika Hans from the position of Chief People Officer (CPO), effective December 15, 2025. The resignation was tendered due to personal commitments and has been accepted by the company. This change in leadership may have an impact on the company's HR strategies and employee relations. Investors should monitor the company's future announcements regarding the appointment of a new CPO and any potential changes in HR policies.
முக்கிய அம்சங்கள்
Mrs. Geetika Hans resigned as Chief People Officer (CPO).Resignation is effective from December 15, 2025.The reason for resignation is personal commitments.Reference is made to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.
👀 கவனிக்க வேண்டியவை
Investors should monitor MPS Limited's announcements for the appointment of a new Chief People Officer and any potential impact on the company's human resource strategies. No immediate action is required, but stay informed about leadership transitions.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
